Related Content
Search Google Scholar for:
|
|
Science 31 July 1987:
Vol. 237. no. 4814, pp. 532 - 535
DOI: 10.1126/science.2440107
|
|
Articles
Science, Vol 237, Issue 4814, 532-535
Copyright © 1987 by American Association for the Advancement of Science
The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts
GQ Daley,
J McLaughlin,
ON Witte,
and
D Baltimore
The v-abl oncogene of the Abelson murine leukemia virus (A-MuLV) is known to efficiently transform NIH/3T3 fibroblasts in vitro and to cause an acute lymphosarcoma in susceptible murine hosts. The role of its relative, the bcr/abl gene product, in the etiology of human chronic myelogenous leukemia (CML) remains speculative. To assess the transforming properties of the bcr/abl gene product, complementary DNA clones encoding the CML-specific P210 bcr/abl protein were expressed in NIH/3T3 fibroblasts. In contrast to the v-abl oncogene product P160, the P210 bcr/abl gene product did not transform NIH/3T3 cells. Cell lines were isolated that expressed high levels of the P210 bcr/abl protein but were morphologically normal. During the course of these experiments, a transforming recombinant of bcr/abl was isolated which fuses gag determinants derived from helper virus to the NH2-terminus of the bcr/abl protein. This suggests that a property of viral gag sequences, probably myristylation-dependent membrane localization, must be provided to bcr/abl for it to transform fibroblasts.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
- Regulation of Cellular Transformation by Oncogenic and Normal Abl Kinases.
- J. Suzuki and T. Shishido (2007)
J. Biochem.
141, 453-458
| Abstract »
| Full Text »
| PDF »
- OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.
- D. L. White, V. A. Saunders, P. Dang, J. Engler, A. C. W. Zannettino, A. C. Cambareri, S. R. Quinn, P. W. Manley, and T. P. Hughes (2006)
Blood
108, 697-704
| Abstract »
| Full Text »
| PDF »
- Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias.
- S. Jaiswal, D. Traver, T. Miyamoto, K. Akashi, E. Lagasse, and I. L. Weissman (2003)
PNAS
100, 10002-10007
| Abstract »
| Full Text »
| PDF »
- FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.
- L. M. Kelly, Q. Liu, J. L. Kutok, I. R. Williams, C. L. Boulton, and D. G. Gilliland (2002)
Blood
99, 310-318
| Abstract »
| Full Text »
| PDF »
- The molecular biology of chronic myeloid leukemia.
- M. W. N. Deininger, J. M. Goldman, and J. V. Melo (2000)
Blood
96, 3343-3356
| Full Text »
| PDF »
- Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.
- E. Weisberg and J. D. Griffin (2000)
Blood
95, 3498-3505
| Abstract »
| Full Text »
| PDF »
- In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment.
- C. Cobaleda and I. Sanchez-Garcia (2000)
Blood
95, 731-737
| Abstract »
| Full Text »
| PDF »
- A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia.
- C. Cobaleda, N. Gutierrez-Cianca, J. Perez-Losada, T. Flores, R. Garcia-Sanz, M. Gonzalez, and I. Sanchez-Garcia (2000)
Blood
95, 1007-1013
| Abstract »
| Full Text »
| PDF »
- Dual Transforming Activities of the FUS (TLS)-ERG Leukemia Fusion Protein Conferred by Two N-Terminal Domains of FUS (TLS).
- H. Ichikawa, K. Shimizu, R. Katsu, and M. Ohki (1999)
Mol. Cell. Biol.
19, 7639-7650
| Abstract »
| Full Text »
| PDF »
- Bcr-Abl with an SH3 Deletion Retains the Ability To Induce a Myeloproliferative Disease in Mice, yet c-Abl Activated by an SH3 Deletion Induces Only Lymphoid Malignancy.
- A. W. Gross, X. Zhang, and R. Ren (1999)
Mol. Cell. Biol.
19, 6918-6928
| Abstract »
| Full Text »
| PDF »
- STAT5 Activation by BCR-Abl Contributes to Transformation of K562 Leukemia Cells.
- R. P. de Groot, J. A.M. Raaijmakers, J.-W. J. Lammers, R. Jove, and L. Koenderman (1999)
Blood
94, 1108-1112
| Abstract »
| Full Text »
| PDF »
- Integrins, Oncogenes, and Anchorage Independence.
- M. A. Schwartz (1997)
J. Cell Biol.
139, 575-578
| Full Text »
| PDF »
- A BCR-ABLp190 Fusion Gene Made by Homologous Recombination Causes B-Cell Acute Lymphoblastic Leukemias in Chimeric Mice With Independence of the Endogenous bcr Product.
- A. Castellanos, B. Pintado, E. Weruaga, R. Arevalo, A. Lopez, A. Orfao, and I. Sanchez-Garcia (1997)
Blood
90, 2168-2174
| Abstract »
| Full Text »
| PDF »
- Direct Binding of CRKL to BCR-ABL Is Not Required for BCR-ABL Transformation.
- C. Heaney, K. Kolibaba, A. Bhat, T. Oda, S. Ohno, S. Fanning, and B. J. Druker (1997)
Blood
89, 297-306
| Abstract »
| Full Text »
| PDF »
- An Activating Mutation in the ATP Binding Site of the ABL Kinase Domain.
- P. B. Allen and L. M. Wiedemann (1996)
J. Biol. Chem.
271, 19585-19591
| Abstract »
| Full Text »
| PDF »
- Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
- G. Daley, R. Van Etten, and D Baltimore (1990)
Science
247, 824-830
| Abstract »
| PDF »
- c-Abl Tyrosine Kinase Binds and Phosphorylates Phospholipid Scramblase 1.
- J. Sun, J. Zhao, M. A. Schwartz, J. Y. J. Wang, T. Wiedmer, and P. J. Sims (2001)
J. Biol. Chem.
276, 28984-28990
| Abstract »
| Full Text »
| PDF »
|
|
